Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
← catalyst calendarNCT04735978 · readout in 103 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →. With Bristol-Myers Squibb.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
123estimated
Sites
13
Countries
France, Greece, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-29 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Interventions
- Biological: RP3
- Biological: Nivolumab
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose limiting toxicities (DLTs) during the DLT period
measured From Day 1 up to 30 days after last dose
Incidence and severity of treatment emergent adverse events (TEAEs)
measured From Day 1 up to 60 days after last dose
Incidence and severity of serious adverse events (SAEs)
measured From Day 1 up to 60 days after last dose
Incidence of TEAEs ≥ Grade 3
measured From Day 1 up to 60 days after last dose
Percentage of events requiring withdrawal
measured From Day 1 up to last dose (up to 8 weeks in escalation phase and up to 2 years in combination phase)
Recommended phase 2 dose (RP2D) of RP3
measured 7 months
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed